文献速递胸部肿瘤

中心型不可手术早期非小细胞肺癌的立体定向体部放疗:EORTC 22113-08113 LungTech II期试验结果

Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
PubMed 文献 · J Thorac Oncol · 2024-05-22

LungTech是一项国际II期单臂试验,评估8次7.5 Gy立体定向体部放疗(SBRT)治疗中心型不可手术早期非小细胞肺癌的安全性和疗效。因招募不佳提前终止,31例可分析患者3年无局部进展率为81.5%(90%CI 62.7%-91.4%),总生存率61.1%(90%CI 44.1%-74.4%)。≥G3晚期不良事件发生率为19.4%(n=6),包括1例致死性咯血。

要点

  • 3年无局部进展率81.5%(90%CI 62.7%-91.4%),总生存率61.1%(90%CI 44.1%-74.4%)。
  • ≥G3急性不良事件发生率6.5%(n=2),≥G3晚期不良事件发生率19.4%(n=6)。
  • 晚期严重不良事件可在治疗完成后发生,需谨慎管理剂量约束和SBRT后干预。

核心结论

  • LungTech试验提示,8次7.5 Gy SBRT治疗不可手术中心型肺肿瘤可获得可接受的局部控制率。
  • 治疗完成后可能发生晚期严重不良事件。
  • 该SBRT方案是与患者充分讨论风险获益后的可行治疗选择。
  • 为减少潜在致死性毒性,谨慎管理剂量约束和SBRT后干预至关重要。

研究设计与样本

  • 国际II期单臂试验(EORTC 22113-08113 LungTech),评估中心型早期NSCLC的SBRT。
  • 纳入不可手术非转移性中心型NSCLC(T1-T3 N0 M0,≤7cm)患者。
  • 经前瞻性中心影像审查和放疗质量保证后,给予SBRT 8×7.5 Gy。
  • 主要终点为SBRT开始后3年无局部进展概率。
  • 2015年8月至2017年12月,来自6个欧洲国家的39例患者纳入,31例按方案治疗并分析。

主要发现

  • 患者主要为男性(58%),中位年龄75岁;基线合并症主要为呼吸系统(68%)和心脏(48%)。
  • 中位肿瘤大小2.6 cm(范围1.2-5.5),多数为T1(51.6%)或T2a(38.7%)N0 M0,鳞状细胞来源占48.4%。
  • 6例(19.4%)为超中心型肿瘤位置;中位随访3.6年。
  • 3年无局部进展率和总生存率分别为81.5%(90%CI 62.7%-91.4%)和61.1%(90%CI 44.1%-74.4%)。
  • 3年局部、区域和远处进展累积发生率分别为6.7%(90%CI 1.6%-17.1%)、3.3%(90%CI 0.4%-12.4%)和29.8%(90%CI 16.8%-44.1%)。

关键数值与推荐

  • SBRT相关≥G3急性不良事件发生率为6.5%(n=2),包括1例G5肺炎(患者有既往间质性肺病)。
  • SBRT相关≥G3晚期不良事件发生率为19.4%(n=6),包括1例致死性咯血(肺活检后,患者正在接受抗凝治疗)。
  • 3年无局部进展概率81.5%(90%CI 62.7%-91.4%),总生存率61.1%(90%CI 44.1%-74.4%)。
  • 3年局部、区域、远处进展累积发生率分别为6.7%(90%CI 1.6%-17.1%)、3.3%(90%CI 0.4%-12.4%)、29.8%(90%CI 16.8%-44.1%)。

临床怎么用

  • 该SBRT方案(8×7.5 Gy)是与患者充分讨论风险获益后的可行治疗选择。
  • 为减少潜在致死性毒性,谨慎管理剂量约束和SBRT后干预至关重要。

局限性

  • 试验因与安全性相关的反复招募暂停导致的招募不佳而提前终止。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The international phase II single-arm LungTech trial 22113-08113 of the European Organization for Research and Treatment of Cancer assessed the safety and efficacy of stereotactic body radiotherapy (SBRT) in patients with centrally located early-stage NSCLC. METHODS: Patients with inoperable non-metastatic central NSCLC (T1-T3 N0 M0, ≤7cm) were included. After prospective central imaging review and radiation therapy quality assurance for any eligible patient, SBRT (8 × 7.5 Gy) was delivered. The primary endpoint was freedom from local progression probability three years after the start of SBRT. RESULTS: The trial was closed early due to poor accrual related to repeated safety-related pauses in recruitment. Between August 2015 and December 2017, 39 patients from six European countries were included and 31 were treated per protocol and analyzed. Patients were mainly male (58%) with a median age of 75 years. Baseline comorbidities were mainly respiratory (68%) and cardiac (48%). Median tumor size was 2.6 cm (range 1.2-5.5) and most cancers were T1 (51.6%) or T2a (38.7%) N0 M0 and of squamous cell origin (48.4%). Six patients (19.4%) had an ultracentral tumor location. The median follow-up was 3.6 years. The rates of 3-year freedom from local progression and overall survival were 81.5% (90% confidence interval [CI]: 62.7%-91.4%) and 61.1% (90% CI: 44.1%-74.4%), respectively. Cumulative incidence rates of local, regional, and distant progression at three years were 6.7% (90% CI: 1.6%-17.1%), 3.3% (90% CI: 0.4%-12.4%), and 29.8% (90% CI: 16.8%-44.1%), respectively. SBRT-related acute adverse events and late adverse events ≥ G3 were reported in 6.5% (n = 2, including one G5 pneumonitis in a patient with prior interstitial lung disease) and 19.4% (n = 6, including one lethal hemoptysis after a lung biopsy in a patient receiving anticoagulants), respectively. CONCLUSIONS: The LungTech trial suggests that SBRT with 8 × 7.5Gy for central lung tumors in inoperable patients is associated with acceptable local control rates. However, late severe adverse events may occur after completion of treatment. This SBRT regimen is a viable treatment option after a thorough risk-benefit discussion with patients. To minimize potentially fatal toxicity, careful management of dose constraints, and post-SBRT interventions is crucial.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Levy A, Adebahr S, Hurkmans C, et al. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results. J Thorac Oncol. 2024. PMID: 38788924. doi:10.1016/j.jtho.2024.05.366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。